Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Recruiting 4

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 2Sarcoma, Endometrial Stromal 1Perivascular Epithelioid Cell Neoplasms 1Advanced Breast Cancer 1Adenosarcoma of the uterus 1

Interventions

Specimen Handling 334Magnetic Resonance Spectroscopy 334Radiotherapy 315Cyclophosphamide 295pembrolizumab 281Cisplatin 267Carboplatin 245Drug Therapy 237Blood Specimen Collection 233Biopsy 204Bevacizumab 186Gemcitabine 178venetoclax 172Radiosurgery 169Capecitabine 164Oxaliplatin 163fludarabine 161Nivolumab 156Paclitaxel 155Standard of Care 136Surveys and Questionnaires 130Surgical Procedures, Operative 130Dexamethasone 126Fluorouracil 124Docetaxel 113tislelizumab 110Rituximab 110Cytarabine 104Azacitidine 101atezolizumab 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × OTHER × RAD1901 × Clear all
NCT07467772 2026-05-22

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Dana-Farber Cancer Institute

Phase 2 Recruiting
30 enrolled
GynecologicSarcoma

Adenosarcoma of the uterus, Sarcoma, Endometrial Stromal, Perivascular Epithelioid Cell Neoplasms

NCT07198724 2026-04-09

ERADICATE

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
65 enrolled
Breast

Breast Neoplasms

NCT06382948 2026-04-03

ADELA

MedSIR

Phase 3 Recruiting
240 enrolled
Breast

Advanced Breast Cancer

NCT07222215 2026-01-22

CAPELA

Dana-Farber Cancer Institute

Phase 2 Recruiting
297 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡